Vasculitis & polymyalgia rheumatica
Risk factors for serious infections in ANCA-associated vasculitis
Authors' conclusion
The use of low-dose TMP/SMX is associated with reduced risk of severe infections in patients with AAV treated with either RTX or CYC/AZA.
Study context
- Population
- Participants of the RAVE trial with antibody-associated vasculitis (AAV)
- Participants
- 197 participants
- Comparison
- Patients with vs without severe infections; Rituximab (RTX) vs CYC/AZA
- Primary endpoint
- Risk factors for severe infections (≥grade 3, CTCAE version 3.0)
Methodological detailsCox-regression models
- Cox-regression models
Primary result
As reported in the abstract
Risk factors for severe infections (Cox regression)
- Higher baseline serum IgM levels associated with risk of severe infections
- Higher baseline total CD19+B cell number associated with decreased risk of severe infections
- Pneumocystis jirovecii prophylaxis with TMP/SMX associated with decreased risk of severe infections
- TMP/SMX associated with lower risk of severe infections in both RTX and CYC/AZA
Further findings
Baseline lymphocyte subsets in patients with severe infections
- Lower absolute CD19+ cell numbers in patients with severe infections, with either RTX or CYC/AZA
- CD5+B and CD3+T cells did not differ between groups
Safety
Severe infections occurring within 6 months after trial entry
- Severe infections within 6 months
- 18 of 22 (82%)
- Respiratory tract infections (most common)
- 15/22, 68%
Original publication
Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. Published 26 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →